Interferon sales and marketing update

Revenues slid to $2,000 in the third quarter ended Sept. 30 from $744,000 in the quarter last year. Stanley Schutzbank, executive vice president, said the company booked no product sales in the quarter.

Schutzbank said Alferon N sales have been slow because patients receive laser therapy and acid therapy before they are treated with Alferon. Purdue purchased $3.3 million of the drug in 1992. Schutzbank said Purdue is starting a public awareness campaign that includes a video that doctors can show their patients. ...